Overview

A Study Evaluating the Efficacy and Safety of CKD-506 in Adult Subjects With Moderate-to-Severe Rheumatoid Arthritis and Inadequate Response to Methotrexate

Status:
Completed

Trial end date:
2019-10-29

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to evaluate the effects of CKD-506 on signs and symptoms of RA in subjects with moderate-to-severe RA who are inadequate responders to methotrexate.

Phase:

Phase 2

Details

Lead Sponsor:

Chong Kun Dang Pharmaceutical

Treatments:

Methotrexate